Navigation Links
Improved Genetic Test Product Empowers Individuals to Better Understand Their Unique Nutritional Needs
Date:3/17/2009

Interleukin Genetics' Enhanced General Nutrition Test Report Outlines an Individual's Susceptibility to Poor Vitamin B Metabolism and Oxidative Stress

WALTHAM, Mass., March 17 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that it has created a new, detailed report format and information package for its General Nutrition genetic risk assessment test that enables easy understanding of an individual's genetic pattern as it relates to vitamin B metabolism and response to oxidative stress and free radicals. The test can identify one or more gene variations that may negatively affect an individual's ability to process necessary nutrients, while highlighting nutritional modifications that may be helpful in improving an individual's overall health and wellness.

The Interleukin Genetics General Nutrition test configuration is based on scientific analysis that identifies DNA variations in two genes important to B-vitamin utilization and four genes important in managing oxidative stress. Individuals that show suboptimal variations of the genes tested for B-vitamin metabolism may experience greater health benefits by adding more vitamin B to their diet. In addition, results indicating suboptimal ability to manage oxidative stress suggest that an individual may be at increased risk for cell damage. Both B-vitamins and oxidative stress play important roles in overall health and wellness and have been linked to risk for certain diseases and cancers.

"Evidence-based genetic test developers have a responsibility to individuals to help them make sense of their genetic findings as they relate to specific health and wellness concerns," said Lewis H. Bender, CEO, Interleukin Genetics. "We are pleased to have developed a user-friendly test and report package for general nutrition to help our customers navigate their risk factors and make nutritional and lifestyle decisions that may help enhance their overall health."

Customers placing first-time orders for the test will receive the new report format and information package, while previous customers can also request the new enhanced version. The test report and information package will initially be made available to individuals in the U.S. and Canada under the Gensona(R) brand and marketed by Alticor, Inc.

Each individual that takes the test will receive a tailored report containing a clear interpretation of findings related to their gene type for both B-Vitamin metabolism and suboptimal management of oxidative stress. The report will also include an overview of the individual's genotype, revealing the specific DNA variations studied and whether the result is normal or suboptimal for his or her specific genotype. Clinical data suggests that people with suboptimal genetic variations may benefit from increased antioxidant intake.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Alternext US: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage his or her health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its Alan James Group [or AJG Brands] subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding the Company's ability to develop genetic tests that identify genetic variations that affect vitamin B metabolism, response to oxidative stress and free radicals and other conditions and how such genetic variations affect such conditions, to identify nutritional and lifestyle decisions that favorably affect such conditions, to provide such information in a format tailored to the individual, and to otherwise make progress in advancing the Company's core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the Company's products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those risks and uncertainties described in the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
2. MedQuist Re-launches New, Improved Web Site
3. Gene chip data improved therapy in some patients with incurable cancer
4. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
5. Innovator Award to Berkeley Labs Joe Gray for improved breast cancer screening
6. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
7. Oridion Introduces New Smart Capnography System for Improved Patient Safety
8. Nursing Home Workers From Across the Nation to Rally in for Improved Nursing Home Care
9. Services for patients with BPD need to be improved say psychiatric nurses
10. Demonstration at Carlyle Group Offices Monday as Grassroots Caravan of Caregivers, Senior Advocates Arrives in D.C. to Speak Out for Improved Care, Staffing at Nations Largest Nursing Home Chain
11. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: